Diphtheria toxin

Structure

Diphtheria toxin is a single polypeptide chain of 535 amino acids consisting of two subunits linked by disulfide bridges, known as an A-B toxin. Binding to the cell surface of the B subunit (the less stable of the two subunits) allows the A subunit (the more stable part of the protein) to penetrate the host cell.

The crystal structure of the diphtheria toxin homodimer has been determined to 2.5 Ångstrom resolution. The structure reveals a Y-shaped molecule consisting of three domains. Fragment A contains the catalytic C domain, and fragment B consists of the T and R domains:

• The amino-terminal catalytic domain, known as the C domain, has an unusual beta+alpha fold. The C domain blocks protein synthesis by transfer of ADP-ribose from NAD to a diphthamide residue of eukaryotic elongation factor 2 (eEF-2).
• A central translocation domain, known as the T domain or TM domain, has a multi-helical globin-like fold with two additional helices at the amino terminus but no counterpart to the first globin helix. This domain is thought to unfold in the membrane. A pH-induced conformational change in the T domain triggers insertion into the endosomal membrane and facilitates the transfer of the C domain into the cytoplasm.
• A carboxy-terminal receptor-binding domain, known as the R domain, has a beta-sandwich fold consisting of nine strands in two sheets with Greek-key topology; it is a subclass of immunoglobulin-like fold. The R domain binds to a cell surface receptor, permitting the toxin to enter the cell by receptor-mediated endocytosis.

Mechanism

The diphtheria toxin has the same mechanism of action as the enzyme NAD(+)—diphthamide ADP-ribosyltransferase (). It catalyzes the ADP ribosylation of the unusual amino acid diphthamide in eEF-2 by transferring the ADP-ribosyl group from NAD+. The ADP ribosylation of diphthamide inactivates the eEF-2 protein, thus, inhibiting the translation of mRNA. The catalysed reaction is as follows: : NAD+ + peptide diphthamide \rightleftharpoons nicotinamide + peptide N-(ADP-D-ribosyl)diphthamide.

The exotoxin A of Pseudomonas aeruginosa uses a similar mechanism of action.

The steps involved in generating toxicity are as follows:

1. Processing
2. The leader region is cleaved during secretion.
3. Proteolytic nicking separates A and B subunits, which remain joined by disulfide bonds until they reach the cytosol.
4. The toxin binds to heparin-binding epidermal growth factor precursor (HB-EGF).
5. The complex undergoes endocytosis by the host cell.
6. Acidification inside the endosome induces translocation of the A subunit into the cytosol.
7. Disulfide bonds are broken.
8. The B subunit remains in the endosome as a pore.
9. The A subunit ADP-ribosylates host eEF-2, which is required for protein synthesis; when it is inactivated, the host cannot make protein and thus dies.

Lethal dose and effects

Diphtheria toxin is extraordinarily potent. Diphtheria toxin has also been associated with the development of myocarditis. Myocarditis secondary to diphtheria toxin is considered one of the biggest risks to unimmunized children.

History

Diphtheria toxin was discovered in 1888 by Émile Roux and Alexandre Yersin. In 1890, Emil Adolf von Behring developed an anti-toxin based on the blood of horses immunized with attenuated bacteria. In 1951, Freeman found that the toxin gene was not encoded on the bacterial chromosome, but by a lysogenic phage (corynephage β) infecting all toxigenic strains.

Clinical use

The drug denileukin diftitox uses diphtheria toxin as an antineoplastic agent.

Resimmune is an immunotoxin that is in clinical trials in cutaneous T cell lymphoma patients. It uses diphtheria toxin (truncated by the cell binding domain) coupled to an antibody to CD3ε (UCHT1).

Research

Similar to other A-B toxins, diphtheria toxin is adept at transporting exogenous proteins across mammalian cell membranes, which are usually impermeable to large proteins. This unique ability can be repurposed to deliver therapeutic proteins, instead of the catalytic domain of the toxin.

This toxin has also been used in neuroscientific and cancer research to ablate specific populations of cells which express the diphtheria toxin receptor (heparin-binding EGF-like growth factor). Administration of the toxin into the organism which does not naturally express this receptor (e.g. mice) will result in the selective ablation of the cell population which do express it.

Annotations

References

References

1. (August 2002). "Bacteriophage control of bacterial virulence". Infection and Immunity.
2. (May 1986). "Bacteriophage Involvement in Group A Streptococcal Pyrogenic Exotoxin A Production". Journal of Bacteriology.
3. (January 1996). "Crystal structure of diphtheria toxin bound to nicotinamide adenine dinucleotide". Biochemistry.
4. (1996). "Medical microbiology". Univ. of Texas Medical Branch.
5. (May 1992). "The crystal structure of diphtheria toxin". Nature.
6. (January 1997). "Crystal structure of nucleotide-free diphtheria toxin". Biochemistry.
7. (September 1994). "Refined structure of monomeric diphtheria toxin at 2.3 A resolution". Protein Science.
8. (September 1994). "Refined structure of dimeric diphtheria toxin at 2.0 A resolution". Protein Science.
9. (2015). "The Comprehensive Sourcebook of Bacterial Protein Toxins". Elsevier.
10. (1977). "Diphtheria toxin". Annual Review of Biochemistry.
11. (2015). "125 Jahre Diphtherieheilserum: Das Behring'sche Gold". Deutsches Ärzteblatt.
12. (June 1951). "Studies on the virulence of bacteriophage-infected strains of Corynebacterium diphtheriae". Journal of Bacteriology.
13. (March 1952). "Further observations on the change to virulence of bacteriophage-infected a virulent strains of Corynebacterium diphtheria". Journal of Bacteriology.
14. (2009). "Todar's Online Textbook of Bacteriology". University of Wisconsin.
15. (2010). "Immunotherapy of Cancer".
16. (August 2015). "Efficient Delivery of Structurally Diverse Protein Cargo into Mammalian Cells by a Bacterial Toxin". Molecular Pharmaceutics.
17. (October 2017). "Repurposing bacterial toxins for intracellular delivery of therapeutic proteins". Biochemical Pharmacology.
18. (March 2009). "Selective erasure of a fear memory". Science.
19. (2020). "Investigating Tumor Heterogeneity in Mouse Models". Annual Review of Cancer Biology.